World Vaccine Congress Washington 2024's highly anticipate pre-congress workshops are back!
Designed for in-depth discussions and insights into vaccine progress, our workshops on April 1, 2024 cover various domains, including new vaccine technology, biodefense, antimicrobial resistance, global health, RNA, and vaccine delivery.
Join our pre-congress workshops on April 01, 2024.
Reserve your seat today with our
discount ticket package
,which grants you access to:
Workshops (April 1, 2024)
(a full-day workshop or the flexibility to choose one morning workshop and one afternoon workshop),
Conference Sessions (April 2-4, 2024)
and
Exhibition (April 2-4, 2024)
FULL-DAY WORKSHOPS - 10:00 to 17:00
[W1] BIODEFENSE: Protecting public health from biothreats to pandemics -
Almost full!
How are international governments incentivizing R&D innovation in industry and what multi-stakeholder initiatives are paving the way for a better prepared future?
Agenda :
-
10:00 am:
Workshop leader Opening remarks
-
10:05 am:
Future biothreats and pandemic preparedness: a strategic perspective
-
10:20 am:
Lightening talks on vaccine innovation
-
11:05 am:
Panel - Investment strategies to secure long term funding for outbreaks and threats
-
12:00 pm:
Panel - Accelerating vaccine development through manufacturing innovation
-
Networking break
-
02:00 pm:
Panel - Improving pandemic preparedness to enable rapid vaccine development and deployment: a consoortium initiative
-
03:00 pm:
Panel - Working together to achieve a 100 days mission facility to detect threats at source and control threats
-
04:00 pm:
Q&A and end of workshop summary
Workshop Speakers:
-
Nikki Romanik,
Special Assistant to the President, Deputy Director and Chief of Staff,
Office of Pandemic Preparedness and Response Policy
-
Cristina Casetti
, Deputy Director,
NIAID/NIH
-
Shannon Greene,
BTO, Program Manager,
DARPA
-
Andrew Kilianski,
Program Manager,
ARPA-H
-
Ashim Subedee,
Director, Catalyst Office,
BARDA
-
Malcom Little,
Partner,
Arlington Capital
-
James Coburn,
Advanced Manufacturing Team Lead and Senior Advisor for Emerging Technologies,
FDA
-
Dr Chris Earnhart,
Chied Technology Officer,
JPEO-CBRND Enabling Biotechnologies (JPEO-CBRND-EB)
-
Dr Umesh Shaligram,
Executive Director and Head of R&D,
Serum Institute of India
-
Diane McCarthy,
Senior Director,
USP
-
Dr Bassam Hallis,
Vaccine Development & Evaluation Centre,
UKHSA
-
Cathy Hoath,
Regulatory Affairs Strategy Lead,
CEPI
-
Ruben Rizzi,
Senior Vice President Global Regulatory Affairs,
BioNtech
-
Dr Peter Marks,
Director, CBER,
FDA
-
Carla Vinals,
Head of Regulatory Affairs Infectious Diseases,
Moderna
-
Seth Seaneke,
Deputy Chief Executive ( Health Products & Technologies)
FDA, Ghana
-
Neil Cherian,
Senior Biosecurity and R&D Program Manager
CEPI
-
Rajinder Suri,
CEO,
DVCMN
-
Thomas King,
VP of R&D,
Sabin Vaccine Institute
-
Jane True,
Vice President mRNA Commercial Strategy & Innovation and Global Pandemic Security
Pfizer
-
Dr Amadou Sall
CEO,
Institut Pasteur
-
Luciana Borio,
Venture Partner,
ArchVentures
-
Matt Hepburn,
CMO,
JPEO-CBRND
-
Prof. Isabel Oliver,
Director General of Science & Research and Chief Scientific Advisor,
UK Health Security Agency
-
Joel Denis,
Director General, Centre for Vaccine and Therapeutic Readiness,
Public Health Agency of Canada
-
Hamilton Bennet,
Senior Director, Vaccine Access & Partnerships,
Moderna
-
Zeshan Muhammedi,
Managing Partner,
MBX
-
Stephanie Wisner,
Chief Business Officer,
Centivax Inc.
-
Mike Stebbins,
Manufacturing and Threat Countermeasures Division,
ATI
[W2] ANTIMICROBIAL RESISTANCE: Role of vaccines, mAbs and antibiotics -
Almost full!
A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens?
Agenda:
-
10:00 am:
Chair opening remarks
-
10:10 am:
Accelerating the Development of Novel Tools against AMR
-
10:40 am:
The applocation of phages to treat bacterial infections
-
11:10 am:
Development of next generation sequencing and molecular diagnostics
-
11:40 am:
The significance of robust health and economic data in tackling antimicrobial resistance
-
12:00 pm:
What is our global AMR strategy: ESKAPE and Priority Pathogens
-
Networking break
-
2:00 pm:
Combination Vaccines
-
2:30 pm:
Shigella and ETEC vaccines
-
3:00 pm:
Serotype Independent Pneumococcal Vaccine
-
3:30 pm:
Developing Pseudomonas and Klebsiella vaccines using a reverse vaccinology approach
-
3:45 pm:
Update on C. diff vaccine development
-
4:00 pm:
Defining the value of vaccines against AMR
Workshop Speakers:
-
Dr Anna Jacobs,
Biologist, Antimicrobials Division,
BARDA
-
Dr Richard Alm
, Chief Scientist,
CARB-X
-
Dr Steven Theriault,
CEO & CSO,
Cytophage
-
Claire Wingfield,
Director, Partnerships & Advocacy,
FIND
-
Latifat Okara,
Principal Health Policy & Insights,
The Economist Impact
-
Tim Cooke,
CEO,
Omniose
-
Dr Bret Sellman,
Executive Director, Vaccine and Immune Therapies and Head of Bacteriology and Vaccines Discovery,
Astrazeneca
-
Dr Francesca Micoli,
Director GVGH Innovation Academy and Senior Project Leader,
GSK Vaccine Institute for Global Health
-
Dr Kimberly Taylor,
Senior Scientific Officer, Concept Acceleration Program,
NIAID
-
Dr William Hausdorff,
Public Health Value Proposition Lead,
PATH
-
Dr Chad Porter,
Department Head Translational and Clinical Research Defense Infectious Diseases Directorate,
Naval Medical Research Center
-
Dr Tim Hirst,
CEO,
GPN Vaccines
-
Dr Rebecca Ingram,
Senior Lecturer,
Queens University Belfast
-
Erika Lamberth,
Senior Director, Vaccine Clinica; Research and Development,
Pfizer
-
Dr Jomana Musmar,
Executive Director,
PACCARB
-
Dr Jessica Pickett,
Director, US Vaccines Health Economics and Outcomes Research,
GSK
-
Dr Fadi Makki,
Partner & Director,
BCG
-
Dr John Jernigan,
Chief, Epidemiology Research and Innovations Branch Division of Healthcare Quality Promotion,
CDC
-
Dr Yewande Alimi,
One Health Unit Lead,
Africa CDC
MORNING WORKSHOPS - 10:00 to 13:00
[AM1]
VACCINE TECHNOLOGY - New vaccine platforms -
SOLD OUT
Cutting-edge technologies shaping the future of vaccine development.
Agenda:
-
10:00 am:
Workshop Leader Opening Remarks
-
10:10 am:
Innovating Vaccine Development: The Role of VaxArray in SolaVAX, a novel photochemical inactivation vaccine platform
-
10:30 am:
Revolutionizing mRNA Production: The paradigm-breaking Nfinty continuous RNA system
-
10:45 am:
Update on a Promising Clinical-stage Adjuvant for Intranasal Vaccination
-
11:00 am:
Use of adjuvants to enhance mucosal immunity after vaccination
-
11:15 am:
Expanding the availability of emulsion adjuvants via synthetic biology
-
11:30 am:
Alternative uses for adjuvants & cross-over immunotherapy technologies
-
11:45 am:
Emerging discovery tools and technologies
Workshop Speakers:
-
Dr Wolfgang Leitner,
Chief, Innate Immunity Section,
NIH
-
Dr Izabela Ragan DVM,
Director of Research and Development,
Solaris Vaccines
-
Patrick Thiaville,
Chief Technologies Officer, Nucleic Acids,
Exothera
-
Dr Chad Costley,
CEO & President,
Blue Willow Biologics
-
Dr Lisa Morici,
Associate Professor,
Tulane University School of Medicine
-
Dr Chase Kempinski,
Chief Executive Officer ,
Enepret
-
Dr Jay Evans,
Chief Scientific and Strategy Officer,
Inimmune
& Director of the Center for Translational Medicine,
University of Montana
-
Dr David Dowling,
Scientist, Division of Infectious Diseases, Instructor in Pediatrics, Harvard Medical School,
Boston Children's Hospital, Harvard Medical School
-
Dr Aaron Esser-Kahn,
Professor of Molecular Engineering,
University of Chicago
[AM2]
GLOBAL HEALTH mAbs: Public-Private collaboration for accessible infectious disease mAbs in LMICs -
Almost full!
There are significant gaps in mAbs access and availability in LMICs. Viable models, commercial incentives and pathways to afford access are currently not in place. Find out how Public-Private collaboration will be needed to bridge this gap.
Co-Organized by:
IAVI, Medicines Patent Pool (MPP), Unitaid and Wellcome
Agenda:
-
10:00 am:
Chair opening remarks
-
10:20 am:
Panel - Challenges and opportunities: What are the barriers and unique considerations for mAbs accessibility/availability in LMICs? What advancements have recently been achieved and how can they be further leveraged for infectious disease mAbs?
-
11:20 am:
Panel - What kind of incentives, enablers and partnerships could contribute to broader access to infectious disease mAbs in LMICs?
-
12:20 pm:
Closing remarks
Workshop speakers:
-
Shelly Malhotra,
Executive Director, Global Access,
IAVI
-
Anne-Isabelle Cameron,
Strategy Technical Officer,
Unitaid
-
Abebe Genetu,
Acting PAVM Coordinator,
Africa CDC
-
Gillian Woollett,
VP, Head Reulatory Strategy and Policy,
Samsung Bioepis
-
Mauricio Mendonca,
Director of Institutional Relations,
Sanofi Brazil
-
Rachel Mitrovich,
Director, Global Vaccines Public Policy & Partnerships,
Merck & Co
-
Dr Jim Crowe
, Director,
Vanderbilt Vaccine Center
-
Christopher Lim
,
Chief, Strategic Funds, Pan American Health Organization (PAHO),
WHO
-
Esteban Burrone,
Head of Policy, Strategy and Market Access,
Medicines Patent Pool
-
Tonya Villafana,
Vice President, Global Franchise Head Vaccines & Immune Therapies,
AstraZeneca
-
Tiago Rocca,
Director of Strategic Partnerships and Business Development,
Instituto Butantan
-
Erin Sparrow,
Technical Officer, Vaccine Product & Delivery Research,
WHO
-
Seth Seaneke,
Deputy Chief Executive (Health Products & Technologies),
FDA, Ghana
-
Roy Himawan,
Director of Pharmaceuticals and Medical Device Resilience,
Ministry of Health, Republic of Indonesia
-
Pete Gardner,
Research Lead, Antibodies & Immunity,
Wellcome Trust
[AM3]
RNA: From vaccines to therapeutics -
SOLD OUT
How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?
Agenda:
-
10:00 am:
Chair opening remarks - Next generation RNA vaccines
-
10:10 am:
mRNA vaccines of the future: Bridging the Knowledge Gaps
-
10:25 am:
Beyond respiratory vaccines
-
10:45 am:
Individualized mRNA vaccines
-
11:00 am:
Accessing vast design space with modular high throughput platform for RNA therapeutics and vaccines
-
11:15 am:
Analytical challenges in characterization of multivalent mRNA vaccines
-
11:30 am:
RNABL: A novel RNA delivery platfrom for therapeutic applications
-
11:45 am:
From a preventative vaccine to a therapeutic vaccine
-
12:00 pm:
Panel - Beyond prophylactic vaccines: the future of RNA therapeutics
Workshop Speakers:
-
Prof Jeffrey Coller,
Bloomberg Distinguished Professor of RNA Biology and Therapeutics Professor of Molecular Biology & Genetics,
Johns Hopkins University
-
Dr Sudha Chivukula,
AVP, Head of Discovery Biology, mRNA Center of Excellence,
Sanofi
-
Dr Jacqueline Miller,
SVP, Therapeutic Area Head - Infectious Disease Development,
Moderna
-
Ruben Rizzi,
SVP, Global Regulatory Affairs,
BioNtech
-
Dr Sarit Schwartz,
Head of RNA, Business Development,
Ginkgo Bioworks
-
Dr Micheal Breen,
Scientist,
Tiba Biotech
-
Dr Gautam Sanyal,
Principal Consultant and Founder,
Vaccine Analytics, LLC
-
Dr Jason Zhang,
CEO & Co-Founder,
ZipCode Bio
-
Anna Rose Welch,
Editorial and Community Director, Advancing RNA,
Life Science Connect
-
Dr Gilles Besin,
CSO,
Orbital Therapeutics
-
Dr Gopi Shanker,
CSO,
Beam Therapeutics
-
Andrew Geall,
Chief Development Officer,
Replicate Bioscience
-
Dr Kate Zhang,
Chief Scientific Officer,
Hopewell Therapeutics
More to be confirmed…
[AM4] STREP A VACCINE INDUSTRY FORUM: Catalyzing Industry Investment in Strep A Vaccine R&D
Bring together vaccine developers to seek alignment and investment in Strep A vaccine development.
Co-Organized by
SAVAC
-
Attendees by invitation only
Workshop Speakers:
-
Dr Jerome Kim,
Director General,
International Vaccine Institute (IVI)
-
Dr Andrew Steer,
Director of Infection, Immunity and Global Health, and Group Leader of the Tropical Diseases Research Group
MCRI
-
Dr Anne Mullin,
Principal,
Shift Health
-
Dr Don Walkinshaw,
Senior Director, Consulting,
Shift Health
[PM1]
VACCINE DELIVERY: Alternative vaccination routes -
SOLD OUT
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.
Agenda:
-
2:00 pm:
Workshop Leader Opening Remarks
-
2:10 pm:
Microneedle Patches for Measles-Rubella Vaccine Delivery: Gamechangers for Measles and Rubella Elimination
-
2:30 pm:
Redefining Access: Prefilled Injectables for Safe and Efficient Vaccinations
-
3:00 pm:
RNA & MAP - Combining Breakthrough Innovations
-
3:15 pm:
Formulate the future: cutting-edge technologies for manufacturing of sustainable components of vaccine delivery systems
-
3:30 pm:
CeraMAPs(tm), the next generation Micro-needle Array Patches
-
3:45 pm:
Improving the performance of vaccines with precision-delivery technologies
-
4:15 pm:
Consumer Preference for High-Density Microarray Patch to Enable Skin Delivery of Vaccines
-
4:30 pm:
HalDisc®: A Fast and Reliable Novel Device for Vaccination
Workshop Speakers:
-
Dr Rochelle Chaiken,
Chief Medical Officer,
Vaxxas
-
Mariacristina Castelli,
Chief CLinical and Regulatory Affairs Officer,
Hisamitsu
-
Nathalie Landry,
CSO,
PharmaJet
-
Mike G.W. de Leeuw,
CEO,
MyLife Technologies
-
Dr Stephen Crooke,
Vaccine Immunology Lead,
Viral Vaccine Preventable Diseases,
Center for Disease Control and Prevention
-
Dr Edward Kelley,
Chief Global Health Officer,
Apiject
-
Dr Markus Winterberg,
Head of Analytical Development, Microbiology, and Quality Control,
LTS Lohmann
-
Dr Dennis Christensen,
Global Head of R&D, Adjuvant Systems,
CRODA
-
David Hoey,
President & CEO
,
PharmaJet
[PM3] BEYOND EFFICACY: Innovating vaccine development and implementation for impact -
Limited seats left!
Vaccine efficacy is only one determinant of vaccine impact. This workshop will explore innovations throughout the development of a novel vaccine which may ensure better access and equity.
Whichever the theme each year, it will challenge our thinking, our dogmas and perhaps reveal new horizons. It honours
Dr Mike Watson
, a true vaccinologist and original thinker.
Agenda:
-
2:00 pm:
Workshop leader opening remarks
-
2:20 pm:
Presentation 1: Program implementation – Electronic Immunization Records are foundational for equitable vaccination (and PHC)
-
2:50 pm:
Presentation 2: Innovating to deliver a pandemic vaccine in 100 days
-
3:20 pm:
Presentation 3: How do we make sure that the vaccines we develop are what countries want?
-
3:50 pm:
Panel Discussion
Workshop Speakers:
-
Dr Angus Thomson,
Principal,
Irimi Company
-
Rustum Nabiev,
Director,
Shifo Foundation
-
Dr Rebecca Farkas,
Director of Dept of R&D Innovations
CEPI
-
Dr William Hausdorff,
Public Health Value Proposition Lead
PATH
-
Hamilton Bennett,
Senior Director, Vaccine Access and Partnerships,
Moderna
[PM4] ADULT VACCINATION: New vaccines, new opportunities to protect public health -
Limited seats left!
This panel session explores solutions that can reshape adult vaccination through policy and system level change (e.g., closing coverage gaps, timeliness of coverage, data systems, equity considerations, alternative administration sites), provider level (e.g., simplification and standardization of recommendations, system prompts), and consumer level (e.g., healthy aging, empowerment and education).
2pm - 3:30pm
Workshop Speakers:
-
Phyllis Arthur,
Senior Vice President, Infectious Diseases & Emerging Science Policy,
Biotechnology Innovation Organization (BIO)
-
Abby Bownas,
Partner,
NVG
-
Sue Peschin,
President & CEO,
Alliance for Aging Research
-
Arthur Hirt,
SVP, Vaccines Business Unit,
Merck
[PM5] ACHIEVING THE WHO CERVICAL CANCER ELIMINATION GOAL: Why partnerships matter -
Limited seats left!
This panel session will highlight the importance of innovation in driving progress towards the WHO’s elimination targets, and how partnerships between industry and other multi-sectoral partners working towards achieving cervical cancer elimination has helped accelerate progress towards these targets.
3:35pm - 5pm
Workshop Speakers:
-
Kate Mevis,
Executive Director, U.S. Federal & State Vaccine Policy, Global Vaccines Policy & Partnership,
Merck
-
Anuradha Gupta,
President of Global Immunization,
Sabin Vaccine Institute
-
Dr. Catherine Young,
Office of Science and Technology Policy,
White House
-
Speaker from
ACS
-
Speaker from
USG
-
Speaker from
Roche Diagnostics